CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics
company, announced today that it will report financial results for the
first quarter ending March 31, 2019 on Wednesday, May 1, 2019, before
the U.S. financial markets open.
Management will provide an update on the Company and discuss first
quarter 2019 results as well as expectations for the future via
conference call on Wednesday, May 1, 2019 at 8:30 am ET. To access the
call, please dial 800-289-0438 (domestic) or 323-794-2423
(international) five minutes prior to the start time and refer to
conference ID 4935120. A replay of the call will be available beginning
at 11:30 am ET on the day of the call. To access the replay, please dial
888-203-1112 (domestic) or 719-457-0820 (international) and refer to
conference ID 4935120.
A live audio webcast of the call will be available on the Investors
section of the Company’s website, www.alnylam.com.
An archived webcast will be available on the Alnylam website
approximately two hours after the event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is
leading the translation of RNA interference (RNAi) into a whole new
class of innovative medicines with the potential to transform the lives
of people afflicted with rare genetic, cardio-metabolic, hepatic
infectious, and central nervous system (CNS)/ocular diseases. Based on
Nobel Prize-winning science, RNAi therapeutics represent a powerful,
clinically validated approach for the treatment of a wide range of
severe and debilitating diseases. Founded in 2002, Alnylam is delivering
on a bold vision to turn scientific possibility into reality, with a
robust discovery platform. Alnylam’s first U.S. FDA-approved RNAi
therapeutic is ONPATTRO® (patisiran) lipid complex injection
available in the U.S. for the treatment of the polyneuropathy of
hereditary transthyretin-mediated (hATTR) amyloidosis in adults. In the
EU, ONPATTRO is approved for the treatment of hATTR amyloidosis in
adults with stage 1 or stage 2 polyneuropathy. Alnylam has a deep
pipeline of investigational medicines, including five product candidates
that are in late-stage development. Looking forward, Alnylam will
continue to execute on its “Alnylam 2020” strategy of building a
multi-product, commercial-stage biopharmaceutical company with a
sustainable pipeline of RNAi-based medicines to address the needs of
patients who have limited or inadequate treatment options. Alnylam
employs over 1,000 people worldwide and is headquartered in Cambridge,
MA. For more information about our people, science and pipeline, please
and engage with us on Twitter at @Alnylam
or on LinkedIn.
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom